<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">neurojour</journal-id><journal-title-group><journal-title xml:lang="ru">Неврологический журнал имени Л.О. Бадаляна</journal-title><trans-title-group xml:lang="en"><trans-title>L.O. Badalyan Neurological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2686-8997</issn><issn pub-type="epub">2712-794X</issn><publisher><publisher-name>ФГАУ «НМИЦ здоровья детей» Минздрава России</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.46563/2686-8997-2023-4-2-84-87</article-id><article-id custom-type="edn" pub-id-type="custom">dnqefq</article-id><article-id custom-type="elpub" pub-id-type="custom">neurojour-98</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Отмена противоприступной терапии у пациентов с идиопатическими генерализованными эпилепсиями: ретроспективный анализ риска рецидива приступов</article-title><trans-title-group xml:lang="en"><trans-title>Discontinuation of anticonvulsant therapy in patients with idiopathic generalized epilepsy: risk factors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-9735-480X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>Надежда Леонидовна</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>Nadezhda L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Врач невролог-эпилептолог Областного эпилептологического центра на базе ОКДЦ, 344010, Ростов-на-Дону.</p><p>e-mail: nadezhdakiml83@gmail.com</p></bio><bio xml:lang="en"><p>MD, Region Epileptology Center, Rostov-on-Don, 344010, Russian Federation.</p><p>e-mail: nadezhdakiml83@gmail.com</p></bio><email xlink:type="simple">nadezhdakiml83@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-5289-2584</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевкун</surname><given-names>Павел А.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevkun</surname><given-names>Pavel A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6482-3792</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ямин</surname><given-names>Максим А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yamin</surname><given-names>Maxim A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГАУ Ростовской области «Областной консультативно-диагностический центр»; ФГБОУ ВО «Ростовский государственный медицинский университет<country>Россия</country></aff><aff xml:lang="en">Regional Consulting and Diagnostic Center; Rostov State Medical University<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ГАУ Ростовской области «Областной консультативно-диагностический центр»<country>Россия</country></aff><aff xml:lang="en">Regional Consulting and Diagnostic Center<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>08</month><year>2023</year></pub-date><volume>4</volume><issue>2</issue><fpage>84</fpage><lpage>87</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ким Н.Л., Шевкун П.А., Ямин М.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Ким Н.Л., Шевкун П.А., Ямин М.А.</copyright-holder><copyright-holder xml:lang="en">Kim N.L., Shevkun P.A., Yamin M.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.neuro-journal.ru/jour/article/view/98">https://www.neuro-journal.ru/jour/article/view/98</self-uri><abstract><sec><title>Введение</title><p>Введение. Идиопатические генерализованные эпилепсии (ИГЭ) составляют примерно 15–20% среди лиц с эпилепсией. Однако нет консенсуса, как отменять противоприступную терапию пациентам с ИГЭ после достижения ремиссии, и что можно рассматривать в качестве факторов риска рецидива приступов.</p><p>Цель — выявление факторов риска рецидива приступов после отмены противоприступной терапии (ППТ) у пациентов с ИГЭ.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведён ретроспективный анализ пациентов с ИГЭ, достигших ремиссии, с последующей попыткой отмены ППТ. В анализ включены 238 больных с генетической генерализованной эпилепсией, из них 209 (88%) больных с ИГЭ. У 143 (68%) больных с ИГЭ достигнута ремиссия. Попытка отмены ППТ была предпринята у 78 (54%) больных.</p></sec><sec><title>Результаты</title><p>Результаты. Рецидив приступов наблюдался у 57 (73%) пациентов. В первые 5 лет после отмены ППТ рецидивировало 90% приступов, половина из которых возникли в первый год. В группе пациентов с детской абсансной эпилепсией отмена терапии была у 6 пациентов, рецидива не наблюдалось ни у одного пациента. У пациентов с юношеской абсансной эпилепсией рецидив был у 8 (57,1%) из 14 пациентов, а в группе с ювенильной миоклонической эпилепсией рецидив наблюдался у 23 (92%) из 25 пациентов. Из 33 пациентов с изолированными генерализованными тонико-клоническими приступами, отменивших ППТ, рецидив был у 26 (78,8%) человек.</p></sec><sec><title>Заключение</title><p>Заключение. Среди эпилептических синдромов, включённых в группу ИГЭ, детская абсансная эпилепсия имеет наиболее благоприятный прогноз после отмены ППТ, а ювенильная миоклоническая эпилепсия — наименее благоприятный прогноз с риском рецидива более 90%.</p></sec><sec><title>Участие авторов</title><p>Участие авторов. Каждый автор внёс равнозначный вклад в написание статьи.</p></sec><sec><title>Финансирование</title><p>Финансирование. Исследование не имело спонсорской поддержки.</p></sec><sec><title>Конфликт интересов</title><p>Конфликт интересов. Авторы декларируют отсутствие явных и потенциальных конфликтов интересов в связи с публикацией данной статьи.</p><p>Соблюдение этических стандартов. Исследование не требует представления заключения комитета по биомедицинской этике или иных документов.</p></sec><sec><title>Благодарность</title><p>Благодарность. Выражаем благодарность Александре Демидовой за её вклад в статистическую обработку полученных данных.</p></sec><sec><title>Поступила 10</title><p>Поступила 10.04.2023Принята к печати 23.05.2023Опубликована 30.06.2023</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Idiopathic generalized epilepsies account for approximately 15-20% of individuals with epilepsy. However, there is no consensus on how to cancel anticonvulsant therapy in patients with these epileptic syndromes after achieving remission, and what can be considered as risk factors for relapse of seizures.</p></sec><sec><title>Purpose</title><p>Purpose: identification of predictors of seizure recurrence after discontinuation of anticonvulsant therapy in patients with idiopathic generalized epilepsy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Retrospective analysis of seizure recurrence after discontinuation of anticonvulsant therapy in patients with idiopathic generalized epilepsy. The analysis included two hundred thirty eight patients with genetic generalized epilepsy (GGE), of which 209 (88%) patients were with idiopathic generalized epilepsy (IGE) and 29 (12%) patients with GGE. 143 (68%) patients with IGE achieved remission. An attempt to cancel anticonvulsant was made in 78 (54%) patients.</p></sec><sec><title>Results</title><p>Results. Seizure recurrence was observed in 57 (73%) patients. 90% of seizure relapses occurred in the first 5 years after discontinuation of therapy, half of the relapses occurred in the first year. In group of patients with childhood absence epilepsy (CAE), therapy was discontinued in 6 patients, relapse — 0. 8/14 (57,1%) patients with juvenile absence epilepsy (JAE) had relapse after therapy discontinuation. The relapse in patients with juvenile myoclonic epilepsy (JME) was 23/25 (92%) and in group of patients with isolated generalized tonic-clinic seizure (IGTCS) was in 26/33 (78,8%).</p></sec><sec><title>Conclusion</title><p>Conclusion. Among the epileptic syndromes included in the group of idiopathic generalized epilepsies, CAE has the most favourable prognosis after discontinuation of anticonvulsant therapy, and JME has the least, with a recurrence risk of more than 90%.</p></sec><sec><title>Contribution</title><p>Contribution. Each author made an equal contribution to the writing of the article. All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.</p><p>Compliance with ethical standards. The study does not require the submission of the opinion of the biomedical ethics committee or other documents.</p></sec><sec><title>Acknowledgements</title><p>Acknowledgements. The study had no sponsorship. We express our gratitude to Alexandra Demidova for her contribution to the statistical processing of the obtained data.</p></sec><sec><title>Conflict of interest</title><p>Conflict of interest. The authors declare no conflict of interest.</p></sec><sec><title>Received</title><p>Received: April 10, 2023Accepted:  May 23, 2023Published: June 30, 2023</p></sec></trans-abstract><kwd-group xml:lang="en"><kwd>idiopathic generalized epilepsy</kwd><kwd>remission</kwd><kwd>seizure recurrence</kwd><kwd>risk factors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L., et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512–21. https://doi.org/10.1111/epi.13709</mixed-citation><mixed-citation xml:lang="en">Scheffer I.E., Berkovic S., Capovilla G., Connolly M.B., French J., Guilhoto L., et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58(4): 512–21. https://doi.org/10.1111/epi.13709</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fisher R.S., Cross J.H., D’Souza C., French J.A., Haut S.R., Higurashi N., et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017; 58(4): 531–42. https://doi.org/10.1111/epi.13671</mixed-citation><mixed-citation xml:lang="en">Fisher R.S., Cross J.H., D’Souza C., French J.A., Haut S.R., Higurashi N., et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017; 58(4): 531–42. https://doi.org/10.1111/epi.13671</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hirsch E., French J., Scheffer I.E., Bogacz A., Alsaadi T., Sperling M.R., et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022; 63(6): 1475–99. https://doi.org/10.1111/epi.17236</mixed-citation><mixed-citation xml:lang="en">Hirsch E., French J., Scheffer I.E., Bogacz A., Alsaadi T., Sperling M.R., et al. ILAE definition of the idiopathic generalized epilepsy syndromes: position statement by the ILAE task force on nosology and definitions. Epilepsia. 2022; 63(6): 1475–99. https://doi.org/10.1111/epi.17236</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mullen S.A., Berkovic S.F. Genetic generalized epilepsies. Epilepsia. 2018; 59(6): 1148–53. https://doi.org/10.1111/epi.14042</mixed-citation><mixed-citation xml:lang="en">Mullen S.A., Berkovic S.F. Genetic generalized epilepsies. Epilepsia. 2018; 59(6): 1148–53. https://doi.org/10.1111/epi.14042</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Camfield P., Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17(2): 117–23. https://doi.org/10.1684/epd.2015.0736</mixed-citation><mixed-citation xml:lang="en">Camfield P., Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015; 17(2): 117–23. https://doi.org/10.1684/epd.2015.0736</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Jallon P., Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005; 46(Suppl. 9): 10–4. https://doi.org/10.1111/j.1528-1167.2005.00309.x</mixed-citation><mixed-citation xml:lang="en">Jallon P., Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005; 46(Suppl. 9): 10–4. https://doi.org/10.1111/j.1528-1167.2005.00309.x</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Wirrell E.C., Grossardt B.R., Wong-Kisiel L.C., Nickels K.C. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011; 95(1-2): 110–8. https://doi.org/10.1016/j.eplepsyres.2011.03.009</mixed-citation><mixed-citation xml:lang="en">Wirrell E.C., Grossardt B.R., Wong-Kisiel L.C., Nickels K.C. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011; 95(1-2): 110–8. https://doi.org/10.1016/j.eplepsyres.2011.03.009</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Seneviratne U., Cook M., D’Souza W. The prognosis of idiopathic generalized epilepsy. Epilepsia. 2012; 53(12): 2079–90. https://doi.org/10.1111/j.1528-1167.2012.03723.x</mixed-citation><mixed-citation xml:lang="en">Seneviratne U., Cook M., D’Souza W. The prognosis of idiopathic generalized epilepsy. Epilepsia. 2012; 53(12): 2079–90. https://doi.org/10.1111/j.1528-1167.2012.03723.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tomson T., Marson A., Boon P., Canevini M.P., Covanis A., Gaily E., et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015; 56(7): 1006–19. https://doi.org/10.1111/epi.13021</mixed-citation><mixed-citation xml:lang="en">Tomson T., Marson A., Boon P., Canevini M.P., Covanis A., Gaily E., et al. Valproate in the treatment of epilepsy in girls and women of childbearing potential. Epilepsia. 2015; 56(7): 1006–19. https://doi.org/10.1111/epi.13021</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chowdhury A., Brodie M.J. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Epilepsy Res. 2016; 119: 62–6. https://doi.org/10.1016/j.eplepsyres.2015.11.012</mixed-citation><mixed-citation xml:lang="en">Chowdhury A., Brodie M.J. Pharmacological outcomes in juvenile myoclonic epilepsy: Support for sodium valproate. Epilepsy Res. 2016; 119: 62–6. https://doi.org/10.1016/j.eplepsyres.2015.11.012</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">The Cochrane Collaboration. Cochrane 2015 Annual Review. Cochrane Library; 2015. Available at: https://www.cochrane.org/news/cochrane-2015-annual-review-now-available</mixed-citation><mixed-citation xml:lang="en">The Cochrane Collaboration. Cochrane 2015 Annual Review. Cochrane Library; 2015. Available at: https://www.cochrane.org/news/cochrane-2015-annual-review-now-available</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Vorderwülbecke B.J., Kirschbaum A., Merkle H., Senf P., Holtkamp M. Discontinuing antiepileptic drugs in long-standing idiopathic generalised epilepsy. J. Neurol. 2019; 266(10): 2554–9. https://doi.org/10.1007/s00415-019-09457-z</mixed-citation><mixed-citation xml:lang="en">Vorderwülbecke B.J., Kirschbaum A., Merkle H., Senf P., Holtkamp M. Discontinuing antiepileptic drugs in long-standing idiopathic generalised epilepsy. J. Neurol. 2019; 266(10): 2554–9. https://doi.org/10.1007/s00415-019-09457-z</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Yang W., Zhang X., Long J., Wu Q., Han Y. Prediction of the recurrence risk in patients with epilepsy after the withdrawal of antiepileptic drugs. Epilepsy Behav. 2020; 110: 107156. https://doi.org/10.1016/j.yebeh.2020.107156</mixed-citation><mixed-citation xml:lang="en">Yang W., Zhang X., Long J., Wu Q., Han Y. Prediction of the recurrence risk in patients with epilepsy after the withdrawal of antiepileptic drugs. Epilepsy Behav. 2020; 110: 107156. https://doi.org/10.1016/j.yebeh.2020.107156</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Pavlović M., Jović N., Pekmezović T. Antiepileptic drugs withdrawal in patients with idiopathic generalized epilepsy. Seizure. 2011; 20(7): 520–5. https://doi.org/10.1016/j.seizure.2011.03.007</mixed-citation><mixed-citation xml:lang="en">Pavlović M., Jović N., Pekmezović T. Antiepileptic drugs withdrawal in patients with idiopathic generalized epilepsy. Seizure. 2011; 20(7): 520–5. https://doi.org/10.1016/j.seizure.2011.03.007</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Galimberti C.A., Manni R., Parietti L., Marchioni E., Tartara A. Drug withdrawal in patients with epilepsy: prognostic value of the EEG. Seizure. 1993; 2(3): 213–20. https://doi.org/10.1016/s1059-1311(05)80130-x</mixed-citation><mixed-citation xml:lang="en">Galimberti C.A., Manni R., Parietti L., Marchioni E., Tartara A. Drug withdrawal in patients with epilepsy: prognostic value of the EEG. Seizure. 1993; 2(3): 213–20. https://doi.org/10.1016/s1059-1311(05)80130-x</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
